e-learning
resources
Stockholm 2002
Monday 16.09.2002
COPD - Drug therapy 2
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The direct costs of exacerbations in COPD and the effect of cilomilast treatment
M. D. Spencer, J. Zhu, D. Izard (Greenford, United Kingdom; Collegeville, United States Of America)
Source:
Annual Congress 2002 - COPD - Drug therapy 2
Session:
COPD - Drug therapy 2
Session type:
Thematic Poster Session
Number:
1588
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. D. Spencer, J. Zhu, D. Izard (Greenford, United Kingdom; Collegeville, United States Of America). The direct costs of exacerbations in COPD and the effect of cilomilast treatment. Eur Respir J 2002; 20: Suppl. 38, 1588
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
The effect of tiotropium in the treatment of patients with COPD
Source: Annual Congress 2010 - COPD: management
Year: 2010
The costs of exacerbations in COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 273s
Year: 2001
The effect of tiotropium in COPD complicated with asthma
Source: Annual Congress 2007 - New insights into the treatment of COPD
Year: 2007
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Effect of roflumilast on hospitalizations in COPD patients
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Ceruloplasmine efficacy in patients with asthma exacerbations
Source: Annual Congress 2011 - Novel mechanisms in lung injury
Year: 2011
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma
Source: Eur Respir J, 57 (2) 2002436; 10.1183/13993003.02436-2020
Year: 2021
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD
Source: Annual Congress 2011 - COPD management
Year: 2011
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients
Source: Eur Respir J 2014; 44: 527-529
Year: 2014
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Evaluation of costs of inhospital treatment of COPD exacerbations
Source: Eur Respir J 2004; 24: Suppl. 48, 64s
Year: 2004
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 430s
Year: 2006
Pharmacologic treatment of exacerbations of COPD
Source: International Congress 2016 – Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society (ERS/ATS) guideline
Year: 2016
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept